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Abstract 
During the last years, a great effort has been invested into developing new 
TRAIL formulations with increased bioactivity, trying to overcome the resistance to 
conventional soluble TRAIL (sTRAIL) exhibited by many primary tumours. In our 
group, we have generated artificial lipid nanoparticles decorated with sTRAIL (LUV-
TRAIL), emulating the physiological TRAIL-containing exosomes by which T-cells 
release TRAIL upon activation. We already demonstrated that LUV-TRAIL has greater 
cytotoxicity against both chemoresistant hematologic tumour cells and epithelial 
carcinoma cells compared to a form of sTRAIL similar to that used in clinical trials. In 
this study we have tested LUV-TRAIL in several human colon cancer cell lines with 
different sensitivity to sTRAIL. LUV-TRAIL significantly improved sTRAIL 
cytotoxicity in all colon cancer cell lines tested. Trying to ascertain the molecular 
mechanism by which LUV-TRAIL exhibited improved cytotoxicity, we demonstrated 
that TRAIL-coated lipid nanoparticles were able to activate DR5 more efficiently than 
sTRAIL, and this relied on LUV-TRAIL ability to promote DR5 clustering on the cell 
surface. Moreover, we show that TRAIL molecules are arranged in higher order 
oligomers only in LUV-TRAIL, which may explain their enhanced DR5 clustering 
ability. Finally, LUV-TRAIL showed significantly better antitumor activity than 
sTRAIL in an in vivo model using HCT-116 xenograft tumours in nude mice, validating 
its potential clinical application. 
Keywords: TRAIL, colorectal cancer, lipid nanoparticles, immunotherapy, DR5 cross-
linking 
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1. Introduction 
Colorectal cancer (CRC) is one of the most frequent solid tumours in western 
countries. In fact, recent estimations indicate that CRC is the third most common cancer 
both in males and females [1]. The survival rate throughout all stages has improved 
mainly due to the implementation of screening programs, leading to the detection of 
CRC in earlier stages, together with the development of more effective treatment 
options. However, CRC still accounts for about 9% of the estimated cancer-related 
deaths [1].  
Resistance of cancer cells to apoptosis is one of the so-called hallmarks of 
cancer [2]. Since impairments in the intrinsic apoptotic pathway are often involved in 
this resistance, targeting the extrinsic apoptotic pathway is especially attractive for 
cancer therapy [3,4]. Among the death ligands capable of triggering apoptosis through 
the extrinsic pathway, CD95L showed a remarkable strong cytotoxic potential on cancer 
cells. However, disappointingly it also displayed a severe systemic toxicity, therefore 
making unrealistic its use as anti-cancer agent [5]. On the other hand, another death 
ligand, namely tumour necrosis factor (TNF)-related apoptosis–inducing ligand 
(TRAIL), was found to be able to induce apoptosis in tumour cells without affecting 
most normal cells [6,7]. Hence, it was soon considered as potentially useful for anti-
cancer therapy [8,9]. However, despite the encouraging initial results, TRAIL-based 
therapies showed very limited therapeutic activity in phase II/III clinical trials carried 
out on a wide variety of human cancers [3,10]. In order to overcome TRAIL resistance, 
better sensitization strategies [11-13], as well as novel TRAIL formulations with 
improved bioactivity can be of great usefulness for its future clinical use [14-17]. 
TRAIL has four membrane-bound receptors in humans: TRAIL-R1/DR4, 
TRAIL-R2/DR5, TRAIL-R3/DcR1 and TRAIL-R4/DcR2 [18-24]. In addition, TRAIL 
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has been described to be able to bind to the soluble receptor osteoprotegerin (OPG)
[25]. Among these five receptors, only DR4 and DR5 are able to transduce the apoptotic 
signal upon TRAIL binding. Although they share high similarity, both receptors present 
certain functional differences. For example, DR5 has been described to present higher 
affinity for TRAIL [26]. However, apparently DR5 requires further clustering, so it can 
only be properly activated by membrane-bound TRAIL or by artificially cross-linked 
versions of the molecule [27,28]. On the contrary, DR4 can readily be activated by 
soluble versions of TRAIL, although cross-linked versions of TRAIL proved again to be 
more active than soluble TRAIL [29]. Regarding the relative contribution of both 
receptors to TRAIL-induced apoptosis, DR4 has been described to be the pre-eminent 
pro-apoptotic receptor in haematological cells, while in epithelial cells expressing both 
receptors DR5 appears to be the main pro-apoptotic receptor [30-34]. However, the 
differential contribution of both receptors is still controversial.  
Our group demonstrated that, in physiological conditions, TRAIL was indeed 
released by activated human T cells in its transmembrane form, inserted in the 
membrane of lipid microvesicles called exosomes [35,36]. On this basis, we have 
generated artificial lipid nanoparticles containing membrane-bound TRAIL (LUV-
TRAIL) resembling those natural exosomes. We already demonstrated that LUV-
TRAIL was more effective inducing apoptosis than soluble TRAIL against leukemia 
cells that presented resistance to soluble TRAIL and chemotherapeutic drugs [37,38] 
and also in epithelial-derived cancer cells [39,40]. This increased cytotoxicity induced 
by LUV-TRAIL was due to a superior DR5 activation, which led to an enhanced DISC 
recruitment [40,41].  
In the present work, we have tested LUV-TRAIL in several human colon tumour 
cell lines with different sensitivity to soluble TRAIL, finding that LUV-TRAIL was 
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more efficient than soluble TRAIL inducing apoptosis in all cancer cells tested. Finally, 
the in vivo antitumor potential of LUV-TRAIL against colon carcinoma cells was tested 
in a model of nude mice xenografted with the human colon carcinoma cell line HCT-
116. This novel TRAIL formulation showed an enhanced antitumor ability, and could 
be potentially useful to improve therapy against colon cancer. 
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2. Materials and Methods 
2.1. Generation of liposomes covered with soluble recombinant TRAIL. 
Large Unilamellar Vesicles (LUV) with soluble recombinant TRAIL (hereafter 
sTRAIL) anchored on their surface were generated as previously described [37,42]. 
Briefly, after generating the lipid nanoparticles, a version of sTRAIL (rTRAIL-His6, 
corresponding to amino acids 95–281, kindly provided by Dr. M. MacFarlane [22]) was 
attached to their surface by incubation at 37ºC for 30 minutes.  
2.2. Cell culture. 
HCT-116, HT29 and CACO-2 cell lines were obtained from ATCC.. Bax-
deficient HCT-116 cells deficient (HCT-116-Bax-/-) were kindly provided by Dr. 
Christoph Borner (Albert-Ludwigs-Universität Freiburg). HCT-116-Bax-/- cells lacking 
expression of Bak (thereafter HCT-116-BB) were generated in our laboratory 
(Fig.S.1.A).  Cell lines were routinely cultured at 37 °C in DMEM medium 
supplemented with 10% foetal calf serum (FCS), 2 mM L-glutamine and 
penicillin/streptomycin (hereafter, complete medium). 
2.3. Cell viability assay. 
Cell viability was quantified by the MTT (3-(4,5-dimethyl)-2,5-diphenyl 
tetrazolium bromide) assay [43] as previously described [39,40]. Data was expressed as 
the percentage of cell viability with respect to control cells (untreated cells for sTRAIL, 
and cells treated with LUVs without TRAIL for LUV-TRAIL). 
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2.4. Clonogenic assay. 
Clonogenic survival was assessed as previously described [40]. Quantification of 
the clonogenic assays was performed measuring the absorbance at 550 nm after 
dissolving crystal-violet with DMSO. The results were expressed as the percentage of 
absorbance with respect to the respective control (same as indicated for cell viability 
assays). 
2.5. Cytotoxicity assays. 
CRC cells (3x104 cells) were treated with different concentrations (1 to 1,000 ng/mL) of 
sTRAIL or LUV-TRAIL for 24 hours. In some experiments, cell death inhibition assays 
were carried out pre-incubating cells for 1 hour prior to the addition of sTRAIL or 
LUV-TRAIL with the blocking anti-human TRAIL mAb (500 ng/mL, clone RIK2, BD 
Biosciences) or with the pan-caspase inhibitor z-VAD-fmk (30 µM, Bachem). Then, 
cell sensitivity to sTRAIL or LUV-TRAIL was analysed by annexin-V staining and in 
some cases, by propidium iodide staining using a FACSCalibur flow cytometer and 
CellQuest software (BD Biosciences). 
2.6. Death receptor expression. 
Cell surface expression of pro-apoptotic death receptors in CRC cell lines was 
analysed incubating 1x105 cells with anti-DR4, anti-DR5 or isotype control PE-
conjugated monoclonal antibodies, (eBioscience) at 4 ºC in PBS containing 5% FCS for 
30 min and analysed by flow cytometry using a FACSCalibur flow cytometer and 
CellQuest software (BD Biosciences). 
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2.7. Nuclear morphology analysis. 
Cytotoxicity assays were performed seeding cells (1x105 cells) onto cover slips 
placed in 6-well plates with complete medium, and treated with sTRAIL and LUV-
TRAIL at 500 ng/mL for 6 hours. After that, nuclear morphology was analysed by 
fluorescence microscopy by staining with Hoechst 33342 (Life Technologies) as 
previously described  [39]. 
2.8. Western blot analysis. 
For protein expression analysis, Western blot was performed as previously 
described [38]. The following antibodies were used to analyse the expression of the 
main proteins involved in the extrinsic apoptotic pathway: anti-caspase-8 (BD 
Biosciences), anti-caspase-3 (Cell Signaling), anti-Bid (BD Biosciences), anti-PARP-1 
(BD Biosciences), anti-Bax (BD Biosciences), and anti-Bak (BD Biosciences). As 
loading control, expression of -actin was analysed using a specific antibody (Sigma). 
For higher-order TRAIL oligomers analysis, sTRAIL or LUV-TRAIL were 
incubated with the indicated amounts of the cross-linker BS3 (Thermo) for 30 minutes 
at room temperature. Then, Tris/HCl was added at a final concentration of 50 mM to 
quench the reaction, and after thorough mixing, the mix was settled for 15 minutes at 
room temperature. Finally, sample buffer containing 1% SDS was added to each 
sample. After heating for 5 minutes at 96ºC, samples were separated by SDS-PAGE in 
gels containing 6% acrylamide/bisacrylamide, and analysed by Western blot. 
For the clustering analysis of TRAIL receptors, HCT-116 cells (10 cm Petri 
dishes at 80% confluence) were treated with sTRAIL or LUV-TRAIL for the indicated 
times. After removal of supernatants, cells were washed with cold PBS and 1 ml of lysis 
buffer containing 1% Triton X-100 was added to each plate. After 15 minutes of 
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incubation at 4ºC, cells were scraped, and centrifuged at 4ºC. Then, cells were collected 
and mixed with sample buffer with or without 50 mM DTT. Samples were separated by 
SDS-PAGE, and TRAIL receptor expression was analysed by Western blot. 
2.9. In vivo antitumor activity. 
Immune-deficient athymic mice, Swiss nu/nu strain, six-week old males 
(Charles River), were used to evaluate in vivo antitumor activity. All experiments in 
mice were carried out according to the European recommendations on animal ethics and 
were approved by the University of Zaragoza Animal Experimentation Ethical 
Committee. Mice were kept under specific standard pathogen-free conditions 
throughout the study. 
Freshly harvested HCT-116 cells (1x106 cells/mouse) were inoculated 
subcutaneously into mice. Once tumours reached a volume of 0.1 cm3, mice were 
randomly divided in 3 groups (4 mice/group): Control, sTRAIL and LUV-TRAIL. 
Thirty-six g/ml of either sTRAIL or LUV-TRAIL, in a total volume of 500 l, were 
injected intra-peritoneally daily during 5 consecutive days. Control group were injected 
with LUVs alone (without TRAIL). Tumours were left to grow for 17 days after last 
injection and then, mice were euthanized. During all the experiment, tumour volumes 
were daily monitored, and tumour volume was calculated using the following formula: 
tumour volume=(LxW2)/2 (where L is longitudinal and W is transverse tumour diameter 
respectively). Relative tumour growth was calculated as follows: relative tumour 
volume = (volume day x/ volume day 0) x100.  
In order to assess whether the tumour-derived cells exhibited a similar 
phenotype than the parental cells, a subcutaneous HCT-116 tumour was surgically 
resected and a single cell suspension was obtained by gentle physical dissociation. 
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Finally, death-receptor expression and sensitivity to sTRAIL and LUV-TRAIL was 
analysed both on tumour-derived and parental cells as above described. 
2.10. Statistical analysis. 
Data were analysed using Prism® software program (GraphPad Software, San 
Diego, CA). Student’s t test was used. All values are expressed as mean ± SD and p <
0.05 was considered statistically significant using the Prism® software program 
(GraphPad Software, San Diego, CA). Student’s t test was used. All values are 
expressed as mean ± SD and p < 0.05 was considered statistically significant. HPLC 
data was analysed using the software OriginPro 8® (OriginLab Corporation, 
Northampton, MA, USA). 
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3. Results 
3.1. LUV-TRAIL show a significant higher cytotoxic ability compared with 
sTRAIL in human CRC cell lines. 
Firstly, we checked the surface expression of the TRAIL receptors DR4 and 
DR5 in all CRC cell lines studied. (Fig.S.2) finding  that all cell lines expressed both 
pro-apoptotic TRAIL receptors. Noteworthy, all cell lines showed a higher expression 
of DR5 than DR4. Then, we characterized the overall sensitivity of the four CRC cell 
lines to both forms of TRAIL. For that, cell viability was analysed after carrying out 
dose-response assays using both sTRAIL and LUV-TRAIL (Fig.1.A,). CRC cell lines 
showed different sensitivities to TRAIL. HCT-116 resulted to be the most sensitive cell 
line to both sTRAIL and LUV-TRAIL, but the LC50 was reduced by almost 3 fold in the 
case of LUV-TRAIL (from around 70 ng/ml for sTRAIL to around 25 ng/ml for LUV-
TRAIL). On the contrary, HCT-116-BB showed a greater resistance to sTRAIL as 
compared to the wild-type cells, clearly showing that these cells are type-II cells 
regarding TRAIL sensitivity, since the lack of Bax and Bak completely protects these 
cells from TRAIL-induced apoptosis. However, LUV-TRAIL managed to have a 
significant effect on this cell line, leading to a cell growth inhibition of almost a 40%. 
HT29 cells showed a low sensitivity to sTRAIL, while LUV-TRAIL reached up to 60% 
of reduction of relative cell viability at the highest dose used. Finally, CACO-2 proved 
to be highly resistant to both forms of TRAIL, showed showing a similar sensitivity 
pattern as HCT-116-BB, being LUV-TRAIL again able to induce a significant decrease 
of cell growth.  
On the other hand, the long-term effect of LUV-TRAIL on the survival and 
proliferation of CRC cell lines was assessed by performing clonogenic assays (Fig.1.B). 
In all cases, treatment with LUV-TRAIL for 24 hours significantly reduced clonogenic 
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survival of CRC cells more efficiently than sTRAIL. These data would indicate that 
LUV-TRAIL not only has a stronger short term effect than sTRAIL but also that it has a 
long-term effect affecting to survival and proliferation of CRC cells. 
To assess if the observed decrease of cell viability implied an apoptotic process, 
several features of apoptosis were analysed. First of all, nuclear morphology after 
TRAIL treatment was studied (Fig.2.A). HCT-116 cells showed typical morphological 
features of apoptotic cell death such as blebbing and cell shrinkage (yellow arrows). 
Remarkably, apoptotic nuclear changes were more numerous and apparent when cells 
were treated with LUV-TRAIL, and importantly these nuclear changes correlated with 
cell death analysed in parallel using PI staining. On the other hand, phosphatidyl-serine 
translocation was studied by annexin-V staining upon treatment with both forms of 
TRAIL (sTRAIL and LUV-TRAIL, Fig.2.B). In HCT-116, HT29 and CACO-2 cells, 
LUV-TRAIL exhibited a greater ability to induce apoptosis than sTRAIL. Altogether, 
these results perfectly correlated with the cell viability assays showed in Fig.1.A in all 
cases except for HCT-116 BB cells, where no apoptosis was observed neither with 
sTRAIL nor with LUV-TRAIL. 
To assess that LUV-TRAIL-induced apoptosis was due to a TRAIL-specific 
effect, pre-incubation with the TRAIL-blocking antibody RIK2 was performed before 
treatment with both TRAIL formulations. In all cases, apoptosis induced by either 
sTRAIL or LUV-TRAIL was entirely abrogated (Fig.2.B) corroborating that apoptosis 
induced by LUV-TRAIL exclusively relied on the presence of TRAIL on the liposome 
surface. In this line, it is important to point out that LUVs alone (without TRAIL on 
their surface) did not show any pro-apoptotic effect in any CRC cell line (see controls in 
Fig.2) Therefore, it could be concluded that the cytotoxic effect of LUV-TRAIL was 
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exclusively due to the action of TRAIL, discarding any non-specific effect that could be 
attributed to the liposomal particles. 
3.2. LUV-TRAIL are able to induce a stronger activation of the extrinsic 
apoptotic pathway than sTRAIL in CRC cell lines. 
To further characterize that cell death induced by LUV-TRAIL was an apoptotic 
process, inhibition assays were carried out using the pan-caspase inhibitor z-VAD-fmk 
(Fig.S3). z-VAD-fmk was able to fully inhibit cell death both in HCT-116 and HT29 
cells when treated with forms of TRAIL indicating that LUV-TRAIL-induced cell death 
is a caspase-dependent process. 
Next, activation of the extrinsic apoptotic pathway was assessed by Western blot 
(Fig.3. and Fig.S.4.A and B). For that, CRC cell lines were treated with sTRAIL or 
LUV-TRAIL for the indicated times (up to 6 hours). As it is shown, LUV-TRAIL 
induced a faster and stronger cleavage of the initiator caspase-8 and the effector 
caspase-3 in HCT-116 and HT29 cells. Furthermore, their specific substrates, Bid and 
PARP1 respectively, were also clearly cleaved, indicating that both caspases were 
indeed functionally activated. In parallel, aliquots taken from every time-point were 
analysed to measure the apoptotic levels by annexin-V staining (Fig.3., lower panels), 
finding that the differences observed in the Western blot were actually reflected in terms 
of apoptosis-induction ability, perfectly correlating. On the other hand, the resistant cell 
line HCT-116 BB showed a clear activation of the initiator caspase-8 and subsequently 
cleavage of its substrate Bid, to the same extent as their parental cell line HCT-116 
(Fig.S4.A). In contrast, caspase-3 cleavage was virtually absent. Noteworthy, while 
parental HCT-116 cells showed high levels of a caspase-3 cleaved fragment of about 30 
kDa upon LUV-TRAIL treatment, in HCT-116 BB only the fragment of 19 kDa was 
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detected. Finally, no apoptosis could be detected (Fig.S.4.C), correlating with the results 
showed in Fig.2. However, surprisingly PARP1 cleavage was quite clear, starting after 
only 1 hour of treatment with LUV-TRAIL. To better characterize this apparent 
discrepancy, caspase-3 activation was quantified by using a colorimetric assay. As 
shown in Fig. S4.E, the activation pattern of caspase-3 in wild-type HCT-116 was in 
agreement with the Western blot in Fig. 3. For HCT-116 BB, caspase-3 activity was 
clearly diminished in comparison to the wild-type cells. However, a marginal activity 
could be detected, which could account for the PARP1 cleavage observed, but would 
not be able to fully undergo apoptosis. Altogether, this is the typical pattern expected 
from a type-II cell line, in which the activation of the mitochondrial apoptotic branch is 
mandatory for the execution of the apoptotic program. Finally, the highly resistant cell 
line CACO-2 showed certain activation of caspase-8 upon LUV-TRAIL treatment, but 
to a much lesser extent than the other cell lines, (Fig.S4.B). Accordingly, some 
activation of caspase-3 and cleavage of PARP-1 could be detected, which correlated 
with the observed slight induction of apoptosis (Fig.S4.D). 
3.3. LUV-TRAIL enhanced pro-apoptotic potential relies on the formation 
of supra-molecular TRAIL oligomers. 
Up to this point it was clear that LUV-TRAIL exhibited a higher pro-apoptotic 
potential than the soluble version of TRAIL. Our hypothesis was that the membrane-
bound TRAIL present in the LUV-TRAIL formulation would form supra-molecular 
TRAIL oligomers that, in turn, would activate the main pro-apoptotic TRAIL receptor 
DR5 more efficiently than sTRAIL. To confirm that assumption, we carried out a cross-
linking analysis in order to see the formation of supra-molecular TRAIL oligomers on 
the liposomal surface. The artificial cross-linker BS3 was added to sTRAIL or LUV-
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TRAIL at increasing concentrations to stabilize the different TRAIL-oligomer 
populations, and samples were resolved by SDS-PAGE and Western Blot analysis 
(Fig.4.A). BS3 cross-linking of LUV-TRAIL allowed the detection of supra-trimeric 
populations of high molecular order. However, these higher-order oligomers could not 
be detected in sTRAIL. In order to study in more detail these high-order oligomers seen 
in LUV-TRAIL, the cross-linker BS3 was added to sTRAIL or LUV-TRAIL to stabilize 
the different TRAIL populations, and samples were analysed by HPLC (Fig.4.B and C). 
In LUV-TRAIL, a population of up to 840 kDa was detected, corresponding to 
approximately 32 TRAIL monomers (around 11 trimers, Fig.4.C), while in sTRAIL 
oligomers were hardly detected without incubation with BS3 (Fig.S.5) and it only 
reached approximately 23 TRAIL monomers (around 8 trimers) after BS3 addition 
(Fig.4.B). 
On the other hand, the actual ability of sTRAIL and LUV-TRAIL to cluster 
TRAIL receptors on the cell surface was assessed on HCT-116 cells by allowing the 
cells to be stimulated with either sTRAIL or LUV-TRAIL for up to one hour, and then 
performing non-reducing SDS-PAGE followed by immunoblotting. As shown in 
Fig.4.D, only treatment with LUV-TRAIL allowed the clear formation of DR5 
oligomers on the target cells. This oligomerization could be detected already from the 
first time point studied (10 minutes), and increased along time. Noteworthy, no DR4 
oligomeric populations  could be detected in any case. 
Finally, to further characterize the relative importance of both TRAIL receptors 
in this scenario, we generated HCT-116 derived sub-lines stably down-regulating the 
expression of DR4 or DR5 (Fig.5.A and Fig.S.6). For that, the sub-lines were treated 
with different concentrations of sTRAIL and LUV-TRAIL to check their relative 
sensitivity. As shown in Fig.5.B, silencing of DR4 induced a remarkable reduction of 
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sensitivity to both TRAIL formulations. This would be clearly indicating that DR4 is 
the main pro-apoptotic receptor in these cells. However, importantly, significant 
differences between sTRAIL and LUV-TRAIL could still be detected at the highest 
concentrations (300 and 1000 ng/ml). 
On the other hand, knockdown of DR5 did not have an important effect on the 
overall sensitivity of the cells neither to sTRAIL nor LUV-TRAIL, but the differences 
between sTRAIL and LUV-TRAIL disappeared (Fig.5.B, right panel). These data 
strongly suggested that the main difference between sTRAIL and LUV-TRAIL is their 
relative ability to activate DR5. Altogether, these results clearly indicated that the 
presence of higher order TRAIL oligomers on the liposomal surface was directly linked 
to the clustering of DR5 on the cell surface, ultimately leading to a higher cytotoxic 
effect. 
3.4. LUV-TRAIL shows a significantly higher in vivo antitumor activity than 
soluble TRAIL in a human tumour CRC xenograft model. 
Before performing in vivo experiments, cytotoxicity assays in 3-D cell cultures 
were carried out. For this purpose, we used a novel technology based on microfluidic 
devices which resembles more accurately the in vivo conditions in which cancer cells 
grow [44-46]. Confirming the in vitro results, LUV-TRAIL showed a higher cytotoxic 
effect than sTRAIL against HCT-116 cells also in 3-D cell cultures (Fig.6.A and B). 
Finally, antitumor efficacy of both sTRAIL and LUV-TRAIL was tested using 
xenografted subcutaneous HCT-116 tumours. In any case, before performing the 
experiment, we wanted to assess whether during the tumour engraftment process the 
cells could undergo a selection process that might affect their phenotype regarding 
TRAIL sensitivity when compared to parental cells. Therefore, HCT-116 cells were first 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
17 
analysed regarding their phenotype before and after forming tumours in nude mice. 
After obtaining a single-cell suspension from a tumour, cells were analysed for TRAIL-
DR expression and overall sensitivity to sTRAIL and LUV-TRAIL in comparison to the 
parental cells (Fig.S7.A and B). As it shown, tumour-derived HCT-116 cells showed a 
similar surface expression pattern of both pro-apoptotic receptors DR4 and DR5 as 
parental cells. Concerning the relative sensitivity to sTRAIL and LUV-TRAIL, the 
tumour derived cells surprisingly showed similar sensitivity to both TRAIL 
formulations. Despite this change in relative sensitivity, we decided to carry out an in 
vivo experiment using a HCT-116 xenograft model (Fig.6.C and D). Mice were treated 
intraperitoneally with daily subcutaneous injections of 36 g of either sTRAIL or LUV-
TRAIL for 5 consecutive days, and tumour growth was monitored. Of note, to reduce 
the volume needed to reach 36 g of TRAIL, the stock solutions of sTRAIL and LUV-
TRAIL were prepared at 72 g/ml, which represented six times the usual concentration 
of LUV-TRAIL (routinely prepared at a TRAIL concentration of 12 g/ml). As this was 
an exceptional condition, to discard any unexpected effect due to the high concentration 
of TRAIL, an in vitro cytotoxic assay using LUV-TRAIL (6x) in comparison with 
normal LUV-TRAIL was performed on HCT-116 cells (Fig.S7.C). As it is shown, both 
LUV-TRAIL formulations showed a similar cytotoxic potential. Therefore, it could be 
assumed that the antitumor activity of LUV-TRAIL (6x) against HCT-116 tumours was 
equivalent to that of LUV-TRAIL. As shown in Fig.6.C and D, LUV-TRAIL clearly 
showed a better antitumor effect than sTRAIL against HCT-116–derived tumours. The 
difference between both forms of TRAIL was clear, being significant already at day 13 
(Fig.6.C). Surprisingly, sTRAIL did not reduce nor delay tumour growth respecting to 
the Control group (Fig.6.D). This would be most likely due to the poor stability and 
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pharmacokinetic profile of sTRAIL [47,48], which would inactivate the molecule by the 
time it reached the tumour site. 
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4. Discussion 
Despite the initial optimism that TRAIL incited as a possible new and highly 
selective antitumor agent, the clinical effectiveness of TRAIL, both in monotherapy and 
in combined regimes, has been disappointing [3,4,10]. It is currently accepted that in 
order to overcome the poor responsiveness of some cancers to recombinant TRAIL 
formulations currently available [17] it appears as absolutely indispensable to improve 
its pro-apoptotic potential by the development of novel TRAIL formulations [15]. 
In this line, our group previously demonstrated that human lymphocytes secrete 
TRAIL preferably associated with lipid vesicles called exosomes [35,36] Aiming to 
mimic this exosome-bound TRAIL, we generated the novel TRAIL formulation LUV-
TRAIL, based on anchoring this death ligand on Large Unilamellar Vesicles (LUV) 
resembling these natural exosomes. LUV-TRAIL has been proved to be much more 
potent than soluble TRAIL both in haematological malignancies [37,38,41] and solid 
tumours [39,40]. Remarkably, the soluble version of TRAIL used in all those studies is 
virtually identical to the version used in clinical trials (Dulanermin®), which confers 
more significance to LUV-TRAIL improved efficiency.
Pursuing to further analyse the effectiveness of LUV-TRAIL in solid tumours, 
we laid our focus on CRC cancer. We tested our liposomal formulation on a panel of 
four different CRC cell lines presenting a heterogeneous sensitivity to sTRAIL induced 
apoptosis. Although in some particular cases LUV-TRAIL showed similar pro-
apoptotic ability than sTRAIL, in general LUV-TRAIL was shown to be more active 
than sTRAIL. Noteworthy, LUV-TRAIL was capable of overcoming the resistance to 
sTRAIL of some CRC cell lines highly resistant to sTRAIL, and induced a more robust 
activation of the caspase cascade than the soluble ligand. Moreover, LUV-TRAIL not 
only showed a greater cytotoxic potential in vitro in the short term, but it also showed a 
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significant advantage over sTRAIL at reducing the clonogenic survival in all cell lines 
tested. 
Among the two TRAIL pro-apoptotic receptors, DR5 has been described as the 
main DR responsible for TRAIL-induced apoptosis in some epithelial-derived cancer 
cells such as breast and ovarian carcinoma [32,34]. Regarding CCR cells, both DRs 
have been implicated in TRAIL-induced apoptosis [52,53]. On the other hand, TRAIL 
exhibits a much stronger cytotoxicity when it is artificially cross-linked, and this 
increased bioactivity directly relies on its ability to cluster its pro-apoptotic receptors in 
supra-molecular structures larger than merely trimers [27,54]. Indeed, it has been 
previously demonstrated that the enhanced clustering of TRAIL receptors is related with 
an improved DISC recruitment [49-51]. In this line, it has been described that DR5 
requires further cross-linking for a correct activation [27,28]. In fact, co-treatment of 
soluble TRAIL with an agonistic anti-DR5 antibody allowed an enhanced DR5 
activation mediated by the artificial cross-linking of this receptor facilitated by the 
agonistic antibody [55,56]. We previously demonstrated that the enhanced cytotoxicity 
showed by LUV-TRAIL in human leukemic cells relied on their higher efficiency for 
promoting DR5 clustering leading to a higher DISC recruitment [41]. In the present 
study, we wanted to corroborate this feature also in CRC cells. First, we were able to 
demonstrate in cell-free assays by Western blot and liquid chromatography the 
existence of high molecular weight TRAIL oligomers only on LUV-TRAIL. Moreover, 
clustering analysis in CRC cells clearly demonstrated that LUV-TRAIL induced a more 
efficient clustering of DR5 than sTRAIL. Altogether, these results strongly suggest that 
the more effective apoptotic signal triggered by LUV-TRAIL relies on its more 
pronounced ability to induce a better clustering of the pro-apoptotic receptors on the 
target cell surface. To fully corroborate that the pro-apoptotic potential of LUV-TRAIL 
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is due to their more efficient activation of DR5, HCT-116 cells stably down-regulating 
expression of either DR4 or DR5 were generated using shRNA. As expected, the HCT-
116 -derived shDR4 or shDR5 cells presented different sensitivities to both TRAIL 
formulations. Thus, in the shDR4 clones, the overall cell death levels were remarkably 
reduced, but a significant difference between sTRAIL and LUV-TRAIL could still be 
observed. On the other hand, down-regulation of DR5 did not produce in general any 
important effect on the cytotoxic potential of either sTRAIL or LUV-TRAIL. However, 
importantly, in shDR5 cells the significant difference between sTRAIL and LUV-
TRAIL disappeared, indicating that DR5 activation was the main differential feature 
determining the improved outcome of LUV-TRAIL. Considering our results altogether, 
although in HCT-116 cells DR4 appeared to be the main pro-apoptotic TRAIL receptor, 
apoptosis induction could indeed be further favoured by the concomitant activation of 
DR5 provided by LUV-TRAIL. This activation was possible by the clustering of DR5, 
only achieved upon LUV-TRAIL stimulation.  
In this regard, the relative apoptotic contribution of DR4 or DR5 in HCT-116 
has been indeed addressed in the literature by using different approaches. Those reports 
showed somehow contradictory results: whilst in some of them DR4 appears to be the 
pre-eminent pro-apoptotic receptor, in others it is DR5 [52,53,57-59]. These differences 
might as well be explained by the use of different agonistic molecules in those studies. 
Some of those studies were conducted using different monoclonal agonistic antibodies 
against DR4 or DR5, however, the use of monoclonal antibodies as TRAIL-receptor 
agonists is a delicate matter. Although originally seen as a more specific and reliable 
way to activate DR4 or DR5, it was later shown that in certain cases those antibodies 
were not able to induce apoptosis on their own and required further crosslinking. An 
additional layer of complexity in this regard relies on the actual localization of the 
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receptors within specific membrane micro-domains on the cell surface, which could be 
directly involved in the requirement for further oligomerization of DR5 between 
different cell lines [60-63]. In any case, it appears that using improved TRAIL-derived 
formulations instead of antibodies might be advantageous given that TRAIL bear the 
potential to simultaneously activate both DR4 and DR5.  
Although LUV-TRAIL has been proved to be more active than sTRAIL in all 
experimental settings tested so far, there are still some caveats regarding its possible use 
as a therapeutic agent. Before testing the in vivo antitumor potential of LUV-TRAIL, we 
first tested its performance in a more complex scenario based on culturing the cells in a 
three-dimensional matrix embedded in a central chamber in small polymer chips 
[64,65]. In this model, sTRAIL or LUV-TRAIL were perfused through lateral channels, 
and the agents should be able to diffuse into the matrix and reach the cells inside the 
chamber, somehow similarly to physiological extravasation processes. In accordance 
with its much bigger size, previous results showed that LUV-TRAIL exhibited a much 
slower diffusion rate through the matrix than sTRAIL (data not shown), which could 
actually represent a serious handicap regarding its pro-apoptotic efficiency. However, 
despite its low diffusion rate, LUV-TRAIL not only retained its cytotoxicity, but it 
showed again a much higher pro-apoptotic ability than sTRAIL. 
Finally, we tested the in vivo potential of sTRAIL and LUV-TRAIL using 
xenografted HCT-116 tumours. Remarkably, LUV-TRAIL showed a significant tumour 
size reduction effect, as compared both to sTRAIL and Control groups. Moreover, 
strikingly no antitumor effect was observed for sTRAIL, which, taking into 
consideration the high sensitivity of HCT-116 to sTRAIL in vitro, clearly suggests that 
the systemic administration seriously affected the stability of the molecule. Although no 
specific pharmacokinetic profiles were measured, these results indirectly suggested that 
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the immobilization of TRAIL on the liposomal surface greatly improved the stability of 
TRAIL, retaining its cytotoxic potential in vivo. In this regard, LUV-TRAIL 
formulation would also be taking advantage of the well-known enhancing permeability 
and retention (EPR) effect. According to the EPR effect, thanks to their size, 
nanoparticles in the range of 100 nm of diameter tend to spontaneously localize in 
tumour sites by extravasation through the leaky defective blood capillary irrigating the 
tumour. This EPR effect has been described to be an inherent property of nanoparticles 
independently of the composition of the particles [66]. 
Although the use of liposomes for the treatment of diseases of different kind has 
been extensively described, liposome platforms have been always used as vehicle to 
encapsulate drugs inside their lumen, improving their stability and pharmacodynamic 
properties [67-69]. However, the original idea of using of liposomes as a platform to 
attach TRAIL on their surface, increasing its bioactivity, was firstly developed and 
described by our group. The present study validates this TRAIL formulation not only as 
a potential tool for the treatment of haematological malignancies as previously reported, 
but also as a novel antitumor therapeutic strategy for colorectal cancer. 
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Figure 1. 
(A) Analysis of cell viability of CRC cell lines after treatment with sTRAIL or 
LUV-TRAIL. Cells were treated with sTRAIL or LUV-TRAIL, and left overnight. The 
following day, cell growth was measured by the MTT assay method. Graphs show the 
mean ± SD of several independent experiments. The number of experiments is indicated 
in every case. (B) Effect of sTRAIL and LUV-TRAIL on clonogenic survival of 
CRC cell lines. Cells were treated with the indicated concentrations of sTRAIL or 
LUV-TRAIL for 24 hours. The following day, medium was carefully replaced, and cells 
were left to grow for 10 more days. Finally, cells were stained with crystal-violet. 
Quantification was performed by dissolving the crystal violet with pure DMSO, and 
measuring the absorbance at 600 nm. Effect of sTRAIL and LUV-TRAIL on the cells is 
presented as percentage of colony formation respecting to control. Bar-plots represent 
the mean ± SD of at least three independent experiments. **p<0.005, ***p<0.001).  
Figure 2. 
(A) Nuclear staining of HCT-116. Cells were treated with sTRAIL or LUV-TRAIL at 
indicated doses (100 and 1000 ng/ml) alone or after pre-incubation with the TRAIL-
blocking antibody RIK for 1 hour, and then subjected to nuclear staining by using 
Hoechst 33342. Yellow arrows indicate apoptotic cells. Cell death was measured in 
parallel by flow cytometry after PI staining. (B) Apoptosis induction of sTRAIL and 
LUV-TRAIL on CRC cell lines. Cells were treated or with sTRAIL or LUV-TRAIL at 
indicated concentrations, and left overnight. The following day, apoptosis induction was 
measured by annexin-V staining. In all CRC cells, pre-incubation with the TRAIL-
blocking antibody RIK for 1 hour, was carried out. Graphs show the mean ± SD of at 
least three independent experiments. *p<0.05, **p<0.005, ***p<0.001.
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Figure 3. 
Analysis of time-course caspase activation in HCT-116 and HT29 cells. Cells were 
treated with sTRAIL or LUV-TRAIL (1000 ng/ml) at the indicated times. Finally, cells 
were lysed, and lysates were subjected to SDS-PAGE and to Western blot analysis 
(upper panels). Aliquots from every time point were collected, and apoptosis levels 
were measured by annexin-V staining (lower panels).
Figure 4. 
(A) Oligomerization status of TRAIL molecules in sTRAIL and LUV-TRAIL. 
Same amount of BS3 cross-linked sTRAIL and LUV-TRAIL was loaded in an 
acrylamide gel. Next, samples were reduced and separated by SDS-PAGE. After 
transferring to a PVDF membrane, different TRAIL populations were assessed by 
Western blot. (B and C) Size-exclusion chromatography of sTRAIL and LUV-
TRAIL oligomer populations. Samples of sTRAIL and LUV-TRAIL cross-linked 
with 1 mM BS3 were loaded in a HPLC column, and molecular masses were 
determined. Separation was performed using a Superdex 200 10/300 GL column. 
Oligomer populations identified by HPLC in sTRAIL and LUV-TRAIL samples were 
indicated below each size-exclusion chromatography plot.
 (D) Clustering of DR4 and 
DR5 upon activation with sTRAIL or LUV-TRAIL. HCT-116 cells (2-3 x 107 cells 
for each condition) were treated with 1000 ng/ml of either soluble TRAIL (sTRAIL) or 
LUV-TRAIL at indicated times (0, 10, 30, and 60 min) and then performing both 
reducing and non-reducing SDS-PAGE followed by immunoblotting. Western blot 
analysis of the DISC components (DR4 and DR5) using specific antibodies was 
performed.
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Figure 5. 
(A) DR expression of HCT-116 clones stably down-regulating DRs. After obtaining 
two different HCT-116 clones stably down-regulating expression of DR4 or DR5 were 
generated by shRNA technology DR4 and DR5 surface expression were analysed by 
flow cytometry. (B) Cytotoxic assays of sTRAIL and LUV-TRAIL on HCT-116 
clones stably down-regulating DRs. HCT-116 clones stably down-regulating 
expression of DR4 or DR5 were treated with increasing concentrations of sTRAIL or 
LUV-TRAIL, and cell growth was measured by MTT. In every graph, results from 
HCT-116 wild-type cells are depicted in light grey to easily compare the results. Graphs 
show the mean ± SD of at least three independent experiments. *p<0.05, ***p<0.001.
Figure 6. 
(A) Polystyrene-based microdevices used in 3-D cytotoxic assays. For cytotoxic 
assay in 3D cell cultures, Polystyrene-based microdevices were used. For 3-D cell 
culture, 4x106 HCT-116 cells/ml were incubated in a collagen hydrogel within the 
central microchamber. After 24 hours, treatment with TRAIL (sTRAIL and LUV-
TRAIL) was perfused through the lateral microchannels for 24 h. Cells were stained 
using a solution containing CA (green, alive cells) and PI (red, dead cells) and 
photographed along all the microdevice height (300 µm) using a Nikon Eclipse Ti 
microscope. Confocal images of one of three independent experiments are shown. 
Original magnification 20x. Scale bar is 400 m. (B) Cell viability was quantified by 
manual counting of live (green)/dead (red) cells. Graphics show the average of the cell 
viability of treated cells expressed as percentage. The results are expressed as the mean 
± SD of at least three experiments. (C) In vivo antitumor activity of sTRAIL and 
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LUV-TRAIL. Nude mice bearing HCT-116 tumours received five consecutive intra-
peritoneal injections of LUVs-alone, sTRAIL (36 g/injection) or LUV-TRAIL (36 
g/injection) on the arrow-pointed days. Relative tumour growth is depicted, calculated 
as the percentage of increase in tumour volume relative to the volume at day 1 (n=4 
tumours/group; mean ± SD). (D). Tumour volumes on the different experimental groups 
at day 22 expressed as the mean ± SD of animals of each group. *p<0.05, ** p<0.01; 
*** p<0.001. 
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HIGHLIGHTS 
High-order TRAIL oligomer formation in TRAIL-coated lipid nanoparticles 
enhances DR5 cross-linking and increases anti-tumor effect against colon 
cancer 
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Highlights:
1. Liposomes with TRAIL show greater cytotoxicity than soluble TRAIL in colon 
cancer cells. 
2. Liposomes with TRAIL overcome resistance to soluble TRAIL in colon cancer cells. 
3. TRAIL anchored to liposome surface form high-order oligomers which in turn, 
induce a more potent clusterization of DR5. 
4. Liposomes with TRAIL show greater in vivo anti-tumor activity than soluble TRAIL. 
